Why one cell type cannot explain the benefit
The starting puzzle is a mismatch between pharmacology and genetics. Malonate, a competitive SDH inhibitor, had already been reported by the same group to promote regeneration after myocardial infarction (MI) in adult mice. SDH is the mitochondrial complex that converts succinate to fumarate in the tricarboxylic acid (TCA) cycle. If the regenerative effect simply reflected more cardiomyocyte division, then permanently removing Sdhb from cardiomyocytes should reproduce it. The paper tests that assumption directly and finds it does not hold.
The authors used two genetic models in which Sdhb is deleted in a chosen cell type, alongside the pharmacological malonate model. They then combined single-nucleus RNA sequencing and single-nucleus ATAC-seq, which measure gene expression and chromatin accessibility in individual nuclei, with CUT&RUN profiling of histone marks. This design lets them ask both which cells change and what chromatin state accompanies the change, rather than inferring mechanism from whole-heart tissue.
The key comparison is between cell-specific deletions. Cardiomyocyte-specific Sdhb deletion increased proliferation markers at early time points but left cardiac function unchanged after MI. Myofibroblast-specific Sdhb deletion reduced fibrosis and improved function without inducing cardiomyocyte proliferation. Neither single deletion phenocopies transient malonate treatment, which the authors interpret as evidence that the drug's benefit requires coordinated effects across cell types and a reversible mode of inhibition.
Cardiomyocyte Sdhb loss gives proliferation without recovery
In cardiomyocyte-specific Sdhb knockout (Sdhbcko) hearts, Ki67, pH3 and Aurora B staining marked cycling cardiomyocytes. The increases were transient: at 2 weeks after tamoxifen induction, Ki67+ cardiomyocytes were higher in Sdhbcko than control hearts (P = 0.0015), and pH3+ and Aurora B+ cardiomyocytes were also elevated (P = 0.0003 and P = 0.0010). By 4 weeks, none of these markers differed significantly between groups.
That transient proliferation did not translate into functional recovery. The paper reports that cardiomyocyte-specific deletion reduced scar area but failed to restore cardiac function after MI. The authors connect this to the reversibility of malonate: transient inhibition allows cardiomyocytes to re-enter the cell cycle and later resume oxidative metabolism and maturation, whereas permanent Sdhb deletion removes the recovery phase. They also note that sustained SDH loss may constrain pyrimidine biosynthesis and induce replication stress, so elevated aspartate in knockout hearts may not be enough to sustain proliferation.
This is the paper's clearest caution against reading proliferation markers as regeneration. A rise in cycling cardiomyocytes is a measured cellular event, not proof of restored pump function, and the two outcomes diverge in the same genetic model.
Myofibroblast Sdhb loss suppresses fibrosis and improves function
The fibroblast arm behaves differently. In myofibroblast-specific Sdhb knockout (Sdhbfko) mice, the fraction of SDHB+ PDGFRα+ cardiac fibroblasts fell at 1 week after MI (P = 0.0001, n = 6 mice per group), confirming effective deletion in the targeted population. At 4 weeks, Sdhbfko hearts showed a lower heart weight-to-body weight ratio (P = 0.0061) and reduced fibrotic area (P = 0.0019) and fibrotic area percentage (P = 0.0055) than controls.
Echocardiography tracked the functional consequence over time. Ejection fraction and fractional shortening did not differ before MI or at 1 week, but were significantly higher in Sdhbfko mice at 2 and 4 weeks (ejection fraction P = 0.0328 and P = 0.0311; fractional shortening P = 0.0245 and P = 0.0246). Surviving myocardial area at 1 week did not differ between groups (P = 0.3395), which argues against the functional gain being explained by greater early cardiomyocyte survival.
The authors interpret this as fibroblasts being a major cellular target of SDH inhibition. In their model, suppressing myofibroblast activation reduces scar deposition, and that antifibrotic effect is sufficient to improve function even without a cardiomyocyte proliferation signal.
Reductive metabolism is coupled to chromatin remodeling
The mechanistic link the paper proposes runs from mitochondrial metabolism to histone marks. SDH inhibition promoted reductive mitochondrial metabolism and remodeled H3K4me3- and H3K27me3-marked chromatin in both cardiomyocytes and fibroblasts. H3K4me3 is generally associated with active promoters and H3K27me3 with repressed regions, so shifts in these marks change which gene programs are available to the cell.
In cardiomyocytes, malonate-treated MI hearts showed 1,419 increased and 913 decreased H3K4me3 peaks, and 696 increased and 1,918 decreased H3K27me3 peaks relative to saline-treated MI hearts. Genes near increased H3K4me3 peaks were enriched for cardiac muscle development, muscle differentiation and regulation of contractile function, while genes near decreased H3K27me3 peaks were enriched for cardiac morphogenesis, cell fate commitment and tissue remodeling. These peak-level enrichments are the paper's evidence that the epigenetic shift favors developmental programs.
Single-nucleus data add a cell-state layer. A cardiomyocyte subcluster enriched in malonate-treated MI hearts showed proregenerative gene expression, including cell-cycle and cardiac development genes, together with increased chromatin accessibility at Ccnd3 and Pdk4 and enriched motifs for MEF2 and FOXK1/FOXK2 factors. In fibroblasts, a malonate-enriched subcluster lost profibrotic expression of Postn, Fn1, Runx1 and Acta2 and gained antifibrotic and chromatin-remodeling genes such as Egr1, Notch1, Kdm6b and Kdm7a. The authors present these as correlated transcriptional and chromatin states, not as a demonstrated causal chain for every gene.
Transient inhibition differs from permanent deletion
The paper's central mechanistic argument rests on a contrast between two ways of lowering SDH activity. Malonate produces transient, reversible inhibition and acts across multiple cell types. Genetic Sdhb deletion permanently disables the complex in one cell type. The authors argue that this difference explains why the drug restores function while single-cell deletions do not.
Their biphasic model holds that transient suppression of oxidative metabolism allows cardiomyocytes to re-enter the cell cycle, and that later restoration of oxidative metabolism supports redifferentiation and completion of regeneration. The malonate-responsive cardiomyocyte subcluster sits between glycolytic and fatty acid oxidative programs, which the authors read as a transitional state consistent with that sequence. Permanent deletion would preclude the restoration step.
This interpretation is the authors' model rather than a directly measured flux experiment. The metabolomic profiling measured steady-state metabolite pools without isotope tracing, so the paper cannot show how TCA intermediates are routed during regeneration. The authors acknowledge that flux-based approaches are needed, and they also note that succinate and malate promoted proliferation in hiPSC-derived cardiomyocytes even though both were reduced in Sdhbcko hearts, suggesting increased turnover rather than simple availability.
The fibroblast arm carries the functional benefit
For readers weighing what matters most in this paper, the decisive comparison is between the two cell-specific models. Cardiomyocyte Sdhb deletion produced the more visually striking phenotype, a transient wave of cardiomyocyte proliferation, yet did not improve post-MI function. Myofibroblast Sdhb deletion produced no cardiomyocyte proliferation signal but did reduce fibrosis and improve ejection fraction and fractional shortening by 2 to 4 weeks. In this system, the antifibrotic arm is the one tied to functional recovery.
That priority comes with explicit scope conditions. The single-nucleus and CUT&RUN analyses were performed at one time point, 14 days after MI, so earlier initiating events may be missed. The cell-specific knockouts cover cardiomyocytes and myofibroblasts but not other cardiac cell types, and the authors note that myeloid populations showed distinct transcriptional signatures between treatment groups. Long-term safety of transient SDH inhibition, including cardiomyocyte maturation, electrical integration and arrhythmogenic risk, remains unknown.
The practical reading is not that cardiomyocyte proliferation is irrelevant, but that in this paper it is insufficient on its own. A candidate SDH-inhibiting strategy should be judged on whether it engages the fibroblast arm and preserves the reversibility that allows cardiomyocytes to mature afterward, rather than on proliferation markers alone.
Sources used in this answer
A metabolic–epigenetic switch governs multicellular cardiac repair following succinate dehydrogenase inhibition
Cell-specific Sdhb deletion shows that myofibroblast SDH loss suppresses fibrosis and improves post-MI function, whereas cardiomyocyte SDH loss only transiently increases proliferation without functional recovery.
